The fragment-based drug discovery market is projected to grow at an annualized rate of ~10%, till 2030

To order this 170+ page report, which features 55+ figures and 80+ tables, please visit https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html

Key Market Insights

 Over 85 firms are involved in providing fragment-based drug discovery-related services; of these, around 40 players claim to offer both libraries and technologies

 Industry stakeholders offer either customized fragment libraries or proprietary screening technologies, a select few claim to provide both; however, the expertise related to fragment optimization is still limited in this domain

 Majority of stakeholders in the competitive market landscape are small / mid-sized firms, offering a variety of services to cater to the needs of a diverse clientele, featuring industry and non-industry players

 Stakeholders are actively expanding their capabilities in order to enhance their respective fragment-based drug discovery service portfolios and thereby, maintain a competitive edge in this upcoming industry

 The rising interest in this field is reflected in the number of partnerships inked in the recent past, involving both international and indigenous stakeholders, and focused on drug discovery for diverse range of indications

 Considering the prevalent trend of drug discovery and approval, we are led to believe that the fragment-based approach has the potential to enable significant time and cost savings

 The market is expected to witness growth at a CAGR of ~10%; the anticipated opportunity is likely to be distributed across various types of screening techniques, services and geographies

For more information, please visit https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html

Table of Contents

1. PREFACE

1.1. Scope of the Report

1.2. Research Methodology

1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview

3.2. Overview of Drug Development

3.3. Drug Discovery Process

3.3.1. Target Identification

3.3.2. Target Validation

3.3.3. Hit Generation

3.3.4. Hit-to-Lead

3.3.5. Lead Optimization

3.4. High-Throughput Screening (HTS) and its Limitations

3.5. Fragment-based Drug Discovery (FBDD)

Press Release: Variation 2 (Format 3)

3.5.1. FBDD Strategies

3.5.2. Screening Techniques Used in FBDD

3.6. Challenges Related to FBDD

3.7. Future Perspectives

4. CURRENT MARKET LANDSCAPE

4.1. Chapter Overview

4.2. Fragment-based Drug Discovery: List of Library and Service Providers

4.2.1. Analysis by Year of Establishment of Company

4.2.2. Analysis by Company Size and Geographical Location

4.2.3. Leading Library and Service Providers: Analysis by Number of Products

4.2.4. Analysis by Geography

4.2.5. Analysis by Type of Service Offered

4.2.6. Analysis by Type of Technique Used

4.2.7. Analysis by Other Services Offered

4.2.8. Analysis by End User

4.3. Fragment-based Drug Discovery: List of Libraries and Technologies

4.3.1. Analysis by Type of Product

5. COMPANY PROFILES: FRAGMENT-BASED DRUG DISCOVERY LIBRARY AND SERVICE

PROVIDERS

5.1. Chapter Overview

5.2. 2bind

5.2.1. Recent Developments and Future Outlook

5.3. Charles River Laboratories

5.3.1. Recent Developments and Future Outlook

5.4. ChemAxon

5.4.1. Recent Developments and Future Outlook

5.5. ComInnex

5.5.1. Recent Developments and Future Outlook

5.6. Creative Biolabs

5.6.1. Recent Developments and Future Outlook

5.7. Creative Biostructure

5.8. CRELUX

5.8.1. Recent Developments and Future Outlook

5.9. Domainex

5.9.1. Recent Developments and Future Outlook

5.10. Evotec

5.10.1. Recent Developments and Future Outlook

5.11. Red Glead Discovery

5.12. SARomics Biostructures

5.13. Shanghai ChemPartner

5.13.1. Recent Developments and Future Outlook

Press Release: Variation 2 (Format 3)

5.14. Sygnature Discovery

5.14.1. Recent Developments and Future Outlook

5.15. Vernalis Research

5.15.1. Recent Developments and Future Outlook

6. PARTNERSHIPS AND COLLABORATIONS

6.1. Chapter Overview

6.2. Partnership Models

6.3. Fragment-based Drug Discovery Services Market: List of Partnerships and Collaborations

6.3.1. Analysis by Year of Partnership

6.3.2. Analysis by Type of Partnership

6.3.3. Analysis by Year of Partnership and Type of Partner

6.3.4. Most Active Players: Analysis by Number of Partnerships

6.3.5. Regional Analysis

6.3.6. Intercontinental and Intracontinental Agreements

7. KEY ACQUISITION TARGETS

7.1. Chapter Overview

7.2. Scope and Methodology

7.3. Scoring Criteria and Key Assumptions

7.4. Potential Strategic Acquisition Targets in North America

7.5. Potential Strategic Acquisition Targets in Europe

7.6. Potential Strategic Acquisition Targets in Asia-Pacific

7.7. Concluding Remarks

8. COMPANY COMPETITIVENESS ANALYSIS

8.1. Chapter Overview

8.2. Methodology

8.3. Key Parameters

8.4. Competitiveness Analysis: Fragment-based Drug Discovery Library and Service Providers

8.4.1. Fragment-based Drug Discovery Library and Service Providers based in North America

8.4.2. Fragment-based Drug Discovery Library and Service Providers based in Europe

8.4.3. Fragment-based Drug Discovery Library and Service Providers based in Asia-Pacific

9. COST SAVING ANALYSIS

9.1. Chapter Overview

9.2. Key Assumptions and Parameters

9.3. Methodology

9.4. Overall Cost Saving Potential Associated with FBDD, 2020-2030

9.5. Concluding Remarks

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS

10.1. Chapter Overview

10.2. Key Assumptions and Forecast Methodology

10.3. Global Fragment-based Drug Discovery Market, 2020-2030

10.4. Global Fragment-based Drug Discovery Market: Distribution by Type of Technique, 2020 and

2030

10.4.1. Fragment-based Drug Discovery Market for X-ray Crystallography, 2020-2030

10.4.2. Fragment-based Drug Discovery Market for Nuclear Magnetic Resonance, 2020-2030

10.4.3. Fragment-based Drug Discovery Market for Surface Plasmon Resonance, 2020-2030

10.4.4. Fragment-based Drug Discovery Market for Other Screening Techniques, 2020-2030

10.5. Global Fragment-based Drug Discovery Market: Distribution by Type of Service, 2020 and 2030

10.5.1. Fragment-based Drug Discovery Market for Library Screening, 2020-2030

Press Release: Variation 2 (Format 3)

10.5.2. Fragment-based Drug Discovery Market for Fragment Screening, 2020-2030

10.5.3. Fragment-based Drug Discovery Market for Fragment Optimization, 2020-2030

10.6. Global Fragment-based Drug Discovery Market: Distribution by End User, 2020 and 2030

10.6.1. Fragment-based Drug Discovery Market for Industry Players, 2020-2030

10.6.2. Fragment-based Drug Discovery Market for Non-industry Players, 2020-2030

10.7. Global Fragment-based Drug Discovery Market: Distribution by Geography, 2020 and 2030

10.7.1. Fragment-based Drug Discovery Market in the US, 2020-2030

10.7.2. Fragment-based Drug Discovery Market in Canada, 2020-2030

10.7.3. Fragment-based Drug Discovery Market in the UK, 2020-2030

10.7.4. Fragment-based Drug Discovery Market in France, 2020-2030

10.7.5. Fragment-based Drug Discovery Market in Germany, 2020-2030

10.7.6. Fragment-based Drug Discovery Market in Spain, 2020-2030

10.7.7. Fragment-based Drug Discovery Market in Italy, 2020-2030

10.7.8. Fragment-based Drug Discovery Market in Rest of Europe, 2020-2030

10.7.9. Fragment-based Drug Discovery Market in China, 2020-2030

10.7.10. Fragment-based Drug Discovery Market in Japan, 2020-2030

10.7.11. Fragment-based Drug Discovery Market in India, 2020-2030

10.7.12. Fragment-based Drug Discovery Market in Rest of Asia-Pacific and Rest of the World, 2020-

2030

11. EXECUTIVE INSIGHTS

11.1. Chapter Overview

11.2. Edelris

11.2.1. Company Snapshot

11.2.2. Interview Transcript: Jean-Yves Ortholand, Co-founder & Chief Executive Officer

11.3. SARomics Biostructures

11.3.1. Company Snapshot

11.3.2. Interview Transcript: Björn Walse, Chief Executive Officer

12. CONCLUDING REMARKS

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]